Medmain key facts
as of Oct 2026- Developer of a cloud-based platform designed to assist in digital pathology through AI-powered image analysis and remote diagnostics.
- Medmain is valued at approximately $21.1M as of Oct 2026 (last reported valuation).
- It has raised $19.6M; the latest was Merger/Acquisition ($14.8M) in Feb 2026.
- Notable investors include Plug and Play Tech Center, J-Startup, Deepcore, One Capital (Tokyo), Fukuoka Growth Next — 20 tracked in total.
- Status: Privately Held (backing).
Medmain's last reported valuation, Feb 2026. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch Medmain: the Monday email on marks, rounds and moves
Medmain funding rounds
No funding rounds for Medmain are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Medmain
20+Medmain valuation
Medmain's last reported valuation was $21.1 million in Feb 2026. No priced round, secondary trade or fund mark has surfaced since.
Medmain investors
20 investors are on record for Medmain, including Plug and Play Tech Center, J-Startup, Deepcore and One Capital (Tokyo).
About Medmain
Developer of a cloud-based platform designed to assist in digital pathology through AI-powered image analysis and remote diagnostics. The company's platform offers deep learning-driven pathological screening, telepathology capabilities, and secure cloud storage to conduct pathological image diagnosis, enabling medical institutions and professionals to enhance diagnostic accuracy and efficiency and improve patient care.
- Sector
- Healthcare
- HQ
- Fukuoka, Japan
- Founded
- 2017
- Employees
- 40
- Website
- medmain.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.